United Therapeutics Corporation beat EPS estimates 75% of the time across 16 reported quarters (12 beats, 4 misses), averaging +4.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $6.82 | $7.27 | +6.6% | Beat | Q2 FY26 call |
| Q1 FY26 | $6.73 | $5.82 | -13.5% | Miss | |
| Q4 FY25 | $6.78 | $7.70 | +13.6% | Beat | Q4 FY25 call |
| Q3 FY25 | $6.89 | $7.16 | +3.9% | Beat | |
| Q2 FY25 | $6.80 | $6.41 | -5.7% | Miss | Q2 FY25 call |
| Q1 FY25 | $6.29 | $6.63 | +5.4% | Beat | |
| Q4 FY24 | $6.10 | $6.19 | +1.5% | Beat | |
| Q3 FY24 | $6.18 | $6.39 | +3.4% | Beat | |
| Q2 FY24 | $6.33 | $5.85 | -7.6% | Miss | |
| Q1 FY24 | $5.63 | $6.17 | +9.6% | Beat | |
| Q4 FY23 | $3.92 | $4.36 | +11.2% | Beat | |
| Q3 FY23 | $4.89 | $5.38 | +10.0% | Beat |
Back to UTHR overview · UTHR holders · UTHR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.